Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $0.4 | $1.4 | $1.6 | $0.5 | ($0.9) | $0.4 | $1.9 | $3.8 | $5.8 | $3.5 | $7.1 | $14.2 | $16.3 | $9.5 | $13.5 | ($2.4) | $11.7 | $10.6 | $16.0 | $21.0 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month EPS is $24.3, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's EPS growth was 25.9%. The average annual EPS growth rates for United Therapeutics Corporation have been 38.6% over the past three years, N/A over the past five years.
Over the last year, United Therapeutics Corporation's EPS growth was 25.9%, which is higher than industry growth of (0.2%). It indicates that United Therapeutics Corporation's EPS growth is Good.